LY 163443

• Description:

  LY 163443 is a selective antagonist of leukotrienes D4 (LTD4) and E4 (LTE4) . LY 163443 can antagonize LTD4-induced contractions of guinea pig ileum, trachea, and lung parenchyma. LY 163443 also inhibits tracheal contractions to LTE4[1][2].

• UNSPSC:

  12352005

• Target:

  Leukotriene Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ly-163443.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(C1=CC=C(C(CCC)=C1O)COC2=CC=C(C=C2)CC3=NN=NN3)=O

• Molecular Formula:

  C20H22N4O3

• Molecular Weight:

  366.41

• References & Citations:

  [1]Fleisch JH, et, al. Evaluation of LY163443, 1-[2-hydroxy-3-propyl-4- ([4- (1H-tetrazol-5-ylmethyl) phenoxy]methyl) phenyl]ethanone, as a pharmacologic antagonist of leukotrienes D4 and E4. Naunyn Schmiedebergs Arch Pharmacol. 1986 May;333 (1) :70-7. |[2]Bitterman H, et, al. Use of a novel peptide leukotriene receptor antagonist, Ly-163443, in splanchnic artery occlusion shock. Prostaglandins Leukot Essent Fatty Acids. 1988 May;32 (2) :63-70.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [97581-70-9]